TABLE 1.
Trabecular and cortical parameters in bones from dogs treated with 25 mg·kg−1 intravenous SNF472 for up to 9 months
| Control (N = 4 male/4 female) | SNF472 (N = 4 male/4 female) | ||
|---|---|---|---|
| Trabecular parameters | |||
| Bone volume fraction (%) | Female | 18.7 (15.39–23.21) | 19.8 (16.7–22.9) |
| Male | 19.3 (15.9–23.8) | 19.3 (16.5–24.4) | |
| Trabecular thickness (mm) | Female | 0.123 (0.111–0.140) | 0.122 (0.107–0.134) |
| Male | 0.119 (0.107–0.136) | 0.128 (0.118–0.137) | |
| Trabecular separation (mm) | Female | 0.425 (0.397–0.455) | 0.403 (0.362–0.450) |
| Male | 0.390 (0.350–0.453) | 0.416 (0.349–0.486) | |
| Trabecular number (mm−1) | Female | 1.49 (1.34–1.73) | 1.67 (1.48–1.81) |
| Male | 1.68 (1.39–1.87) | 1.57 (1.34–1.88) | |
| Cortical parameters | |||
| Cortical area fraction (%) | Female | 61.9 (55.1–69.9) | 67.0 (57.5–75.5) |
| Male | 60.2 (52.1–64.8) | 62.8 (58.2–67.4) | |
| Cortical thickness (mm) | Female | 1.19 (1.06–1.31) | 1.29 (0.97–1.50) |
| Male | 1.27 (1.11–1.41) | 1.24 (1.04–1.37) |
Note: Results are presented as median (95% confidence interval) per dose and sex (n = 4). A Kruskall–Wallis followed by Dunn's post hoc test was used to compare median values between groups. No significant differences were evident between groups (P > 0.05).